Trial Profile

A phase II study of eltrombopag in patients with severe aplastic anemia

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Sep 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eltrombopag (Primary)
Indications Aplastic anaemia
Focus Therapeutic Use

Most Recent Events

02 Sep 2015 According to Ligand Pharmaceuticals media release, Revolade received EU approval as First-in-class Therapy for patients with severe anaplastic anemia.
30 Jul 2015 New trial record
24 Jul 2015 CHMP recommended this drug for EU approval based upon the results of Phase 2 study (ELT112523) and two supporting Phase 2 studies (ELT116826 and ELT116643).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com